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LETTERS TO THE EDITOR
Problems in the Measurement of Lp(a)
(Millimoles per Liter Versus Milligrams Percent)
I am writing you regarding an article by von Eckardstein et al.
published in JACC, Vol. 37, pp. 434–9, 2001, on “Lipoprotein(a)
Further Increases the Risk of Coronary Events in Men With High
Global Cardiovascular Risk.” The authors are to be complimented
for conducting a large study using their PROCAM population
where they were able to obtain a long follow-up and also for
making the measurements in fresh serum, which reduces many of
the errors previously seen in Lp(a) assays.
However, despite these precautions, the study still has a major
problem. In their article, Lp(a) is measured in the units of g/l.
These units have little meaning in terms of the quantity of Lp(a)
present in the plasma, as the (a) of Lp(a) is noted to have a
molecular weight that can vary between 250,000 and 750,000
daltons. This variation is determined by a total of over 30
genetically determined alleles. Thus, there are 30  30, or 900
possible variations in the molecular weight of this protein in the
patient’s plasma, and each patient will have the possibility of any
two of these 900 combinations. With this marked variation in
molecular weight, it is impossible to calculate the true concentra-
tions of this protein in terms of g/l. To do so, one must assume an
average molecular weight for the compound. This is very difficult
because the distribution of variation in the size of the compound is
not random, but is well-known to vary widely in different racial
populations. The only solution to this problem is to use an assay
that measures Lp(a) in units of millimoles per liter. This can be
done either by using antibodies that react only with the nonre-
peating portions of the (a) sequence (i.e., those regions not
included in kringle IV) or by capturing the particles with antibod-
ies to (a) and detecting with antibodies to apo B. Methods for
using these techniques have been published previously.
It is unfortunate that in this large study these methods were not
utilized. As a result, the data are very difficult to interpret because they
represent variations of two factors: 1) variation in the size of (a), which
may well be related to disease and which would be reflected indirectly
in the concentrations measured by methods using a g/l unit; or 2)
variation in the concentration of particles of Lp (a) in the plasma,
which may be determined by many other clinical factors.
It is unfortunate that these methods have become utilized
extensively in the literature. They are leading to a great deal of
confusion and actually represent biochemical artifacts. Until we get
a reasonable standardization of Lp(a) assays, it is very difficult to
interpret any studies such as those reported in the article by Von
Eckardstein et al. I would make a plea for people working in this
area to get together to develop a true measure of the Lp(a) that is
not affected by variations in the molecular size of (a). When such
is done, we can then determine which clinical factors are related to
variations in the concentration of Lp(a) particles (the number of
particles/ml) versus those that are related to genetically determined
differences in the size of (a).
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We are grateful to Dr. Kottke for raising an important point. Lack
of standardization has been a big problem in comparing Lp(a) data
from different studies and in defining the threshold value above
which cardiovascular risk is increased. A working group supported
by the National Institutes of Health/National Heart, Lung and
Blood Institute (NIH/NHLBI) evaluated 22 Lp(a) assays using
reference material developed by the International Federation of
Clinical Chemistry and Laboratory Medicine (IFCC) and a
reference assay designed as proposed by Dr. Kottke (1). Using a
test panel consisting of 30 samples, the coefficients of variation
among systems varied from 6% to 31%, with some assays biased
toward higher and some toward lower Lp(a) values. In agreement
with the point raised by Dr. Kottke, a major source of this bias was
heterogeneity in the size of apo(a). Overall, however, results of the
various Lp(a) assays correlated well. Nevertheless, this bias is an
important factor contributing to discrepancies in the suggested risk
threshold values for Lp(a), which vary from 0.2 g/l to 0.3 g/l. To
put it another way, at a given Lp(a) risk threshold, some assays will
overestimate and some will underestimate the cardiovascular risk,
especially in persons whose Lp(a) concentration is close to the
suggested cutoff.
Thus, we agree with Dr. Kottke that Lp(a) measurements
should be performed with standardized assays to allow comparison
of data and definition of a universally acceptable risk threshold
value. Calibration of the various assays using common reference
material is not sufficient for this purpose, as only 2 of the 22 tests
investigated by the NIH/NHLBI/IFCC working group showed
good agreement with the reference assay despite identical calibra-
tion. Manufacturers should optimize their Lp(a) assays using
well-defined antibodies and evaluate their results obtained by
comparison with a reference test. One alternative to standardized
apo(a) immunoassays might be the measurement of the cholesterol
content of Lp(a), a variable identified as a cardiovascular risk factor
in the Framingham Heart Study (2).
Standardized tests were not available when we measured Lp(a)
in PROCAM more than 15 years ago (3). Despite this, we
consider our data to be clinically useful. Even though the levels
given are in arbitrary units rather than mass concentrations, our
measurements clearly show an elevated level of Lp(a) to be
associated with increased cardiovascular risk, particularly when it
coincides with other risk factors. As outlined above, the risk
threshold value remains to be established and may not be the 0.2
g/l suggested by us, even though this value is close to the 80th
percentile in the population, a cutoff suggested by the NIH/
NHLBI/IFCC working group.
Finally, Lp(a) does not show a stringent dose-response relation-
ship with cardiovascular events (see Fig. 1 of our article, ref. 3). For
this reason, the best way to define a threshold value for cardiovas-
cular risk would be to apply a receiver operating characteristics
curve analysis to results obtained using a standardized Lp(a) assay
in a prospective study.
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